Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study.

Date publication

janvier 2019

Journal

The Lancet. Haematology

Auteurs

Membres identifiés du Cancéropôle Est :
Dr NARDIN Charlée

Tous les auteurs :
Delanoy N, Michot JM, Comont T, Kramkimel N, Lazarovici J, Dupont R, Champiat S, Chahine C, Robert C, Herbaux C, Besse B, Guillemin A, Mateus C, Pautier P, Saïag P, Madonna E, Maerevoet M, Bout JC, Leduc C, Biscay P, Quere G, Nardin C, Ebbo M, Albigès L, Marret G, Levrat V, Dujon C, Vargaftig J, Laghouati S, Croisille L, Voisin AL, Godeau B, Massard C, Ribrag V, Marabelle A, Michel M, Lambotte O

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/30528137

Résumé

Anti-programmed cell death 1 (PD-1) and anti-programmed cell death ligand 1 (PD-L1) antibodies are novel immunotherapies for cancer that can induce immune-related adverse events (irAEs). These adverse events can involve all organs, including the haemopoietic system. Thus far, haematological irAEs (haem-irAEs) have not been extensively characterised. This study aims to provide a comprehensive report of the haem-irAEs induced by anti-PD-1 or anti-PD-L1.

Mots clés

Aged, Antibodies, Monoclonal, Humanized, adverse effects, Antineoplastic Agents, Immunological, adverse effects, Female, Humans, Immunotherapy, adverse effects, Male, Middle Aged, Programmed Cell Death 1 Receptor, drug effects

Référence

Lancet Haematol. 2019 01;6(1):e48-e57